Medical News / Broadcasting from ASRS 2021 - Assuring Optimal Implant Insertion of Port Delivery Systems for Anti-VEGF

Approximately 15 years into the era of anti-VEGF therapies for the treatment of age-related macular degeneration (AMD), the field is set for a significant advancement. Later this month, the US Food and Drug Administration (FDA) will weigh on the application ranbizumab, delivered via port delivery system (PDS), for the treatment of neovascular AMD (nAMD). The indication for the therapy—which has supporting phase 2 and 3 evidence for efficacy, safety, and tolerability in the patient population—would provide clinicians and patients a more manageable long-term solution to anti-VEGF adherence. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
Real-world registry data presented this weekend at the American Society of Retina Specialists (ASRS) 2021 Scientific ... read more
The design of the American Society of Retina Specialists (ASRS) 2021 Scientific Meeting came to represent ... read more
Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends ... read more
In the coming weeks, the US Food and Drug Administration (FDA) will be considering the application ... read more